Bong Koh and Nimish Shah (Venrock)
April 22, 2020 04:34 PM EDT
Financing

Ven­rock joins the biotech VC fundrais­ing game, toss­ing $447M in­to a $4.3B pot of new mon­ey

John Carroll

Editor & Founder

It’s not un­usu­al to find the part­ners at Ven­rock trav­el­ing in the A-list sec­tion of biotech. They like to find some of the more ma­ture …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times